OakChart

Myriad Genetics Inc

MYGNHealthcare·Diagnostics & Research·USA·Small·NASD·Nov 11 • 3:59 PM ET

5.72+0.05 (0.88%)
2026-11-12 04:33 CET
Market cap
548.67 USD m
Revenue, TTM
803.60 USD m
Net income, TTM
-129.10 USD m
Free cash flow, TTM
-33.90 USD m
EPS diluted, TTM
-1.36
P/E
-
Compare

Price

MYGN against its 20, 50 and 200-day averages
2050200miss
3.004.005.006.007.0012.0M24.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MYGNclose 5.7220-day 5.7250-day 4.65200-day 4.615.7252w low

29.3% under the 52-week high of 8.09 on 25 Nov 2025. 52-week low 2.74 on 3 Aug 2026. Last 15 sessions, 25.6% high to low

Volume 0.60× normal · the line is the 50-bar volume average

Profile

MYGN
52-week range, 56% of the way up
2.748.09

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

IndexRUT
Employees2700
IPOOct 06, 1995
Beta1.62
ATR, 14d0.37
Rel volume0.60
Short float9.49%
Insider own7.37%
Inst own93.23%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap548.68M
Enterprise Value650.98M
Income-129.10M
Sales803.60M
Book/sh2.81
Cash/sh1.12
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2700
IPOOct 06, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S0.68
P/B2.03
P/C5.12
P/FCF-
EV/EBITDA-
EV/Sales0.81
Quick Ratio1.77
Current Ratio1.98
Debt/Eq0.78
LT Debt/Eq0.75
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.36
EPS next Y-0.69
EPS next Q-0.22
EPS this Y-1262.81%
EPS next Y1.13%
EPS next 5Y-
EPS past 3/5Y-41.67% -8.03%
Sales past 3/5Y6.72% 5.24%
EPS Y/Y TTM68.56%
Sales Y/Y TTM-2.63%
EPS Q/Q-55.86%
Sales Q/Q-1.46%
EarningsNov 04 AMC
EPS/Sales Surpr.44.89% 5.94%

Ownership

Insider Own7.37%
Insider Trans-0.11%
Inst Own93.23%
Inst Trans-4.92%
ROA-19.31%
ROE-40.23%
ROIC-27.43%
Gross Margin64.58%
Oper. Margin-13.33%
Profit Margin-16.07%
SMA20-0.03%
SMA5022.95%
SMA20024.12%
Trades-

Technical

Shs Outstand95.70M
Shs Float88.86M
Short Float9.49%
Short Ratio3.66
Short Interest8.44M
52W High8.09 -29.25%
52W Low2.74 108.76%
Volatility6.78% 7.00%
ATR (14)0.37
RSI (14)55.20
Beta1.62
Rel Volume0.60
Avg Volume2.30M
Volume1,379,385

Performance

Perf Week-4.98%
Perf Month40.20%
Perf Quarter80.44%
Perf Half Y53.35%
Perf YTD-6.99%
Perf Year-14.37%
Perf 3Y-65.23%
Perf 5Y-81.85%
Perf 10Y-66.92%
Recom3.11
Target Price5.81
Prev Close5.67
Price5.72
Change %0.88%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2026UpgradePPiper SandlerUnderweight → Neutral$5-12.6%
Sep 09, 2026ResumedUUBSNeutral$3.60-37.1%
Sep 01, 2026DowngradePPiper SandlerOverweight → Underweight$2-65.0%
May 21, 2025DowngradeBScotiabankSector Outperform → Sector Perform$6+4.9%
May 08, 2025DowngradeWWolfe ResearchOutperform → Peer Perform
May 07, 2025DowngradeWWells FargoOverweight → Equal Weight$6+4.9%
Apr 09, 2025DowngradeGGuggenheimBuy → Neutral
Mar 12, 2025UpgradePPiper SandlerNeutral → Overweight$11.50 → $12.50+118.5%
Feb 12, 2025InitiatedCCraig HallumBuy$29+407.0%
Dec 10, 2024InitiatedUUBSNeutral$18+214.7%

Peers

Mkt cap
TickerCompanyMkt cap
FLGTFulgent Genetics Inc718.03M
NTRANatera Inc46.38B
LHLabcorp Holdings Inc30.23B
BLLNBilliontoone Inc5.27B
WGSGeneDx Holdings Corp1.65B
DGXQuest Diagnostics Inc28.46B
VCYTVeracyte Inc2.03B
TEMTempus AI Inc14.49B
CSTLCastle Biosciences Inc1.05B
MDXHMDxHealth SA13.98M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kumar RashmiDirectorJun 08 '26Sale4.4615,00066,843171,889Jun 09 04:20 PM
Kumar RashmiDirectorJun 08 '26Proposed Sale4.5915,00068,850Jun 08 11:17 AM
Bisaro PaulDirectorMay 14 '26Buy3.697,50027,63897,441May 14 05:16 PM
Raha Samraat S.President and CEOMar 09 '26Buy5.0040,000199,844493,104Mar 09 07:03 PM
Phanstiel S. LouiseDirectorFeb 26 '26Buy4.8050,407242,105233,951Feb 27 04:46 PM
Phanstiel S. LouiseDirectorFeb 27 '26Buy4.6648,000223,728281,951Feb 27 04:46 PM
Phanstiel S. LouiseDirectorFeb 25 '26Buy4.746,10028,890183,544Feb 27 04:46 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FNDASchwab Fundamental U.S. Small Company ETFAUM: 8.98B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200
  • Myriad Genetics Beats On A Pricing Rebound And Prenatal Exit, But Fading Volume Growth And Widening Losses Keep The Turnaround Unproven (Earnings Whispers)
  • Myriad: Q3 Earnings Snapshot (Associated Press)
  • Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives (GlobeNewswire)
  • Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire) -7.87%
  • Myriad Genetics Has Doubled Since Its Guidance Cut; Now Payer Pricing Must Stop Sliding (Earnings Whispers) +5.41%
  • Labcorp inks Millennium Health buyout to add drug testing services (MedTech Dive)
  • Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers (GlobeNewswire)
  • Labcorp to buy Myriads prenatal health testing unit for $210M (MedTech Dive)
  • Myriad Genetics stock surges on $210M prenatal unit sale (Investing.com) +31.59%
  • Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp (GlobeNewswire)
  • Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire) -8.51%
  • SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (PR Newswire)
  • Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (GlobeNewswire)
  • Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.110-0.200-0.460202.7191.338
2026Q22026-07-30-0.250-0.058-0.456190.7206.039
2026Q12026-05-05-0.090-0.068-0.364200.4202.4211
2025Q42026-02-230.040-0.015-0.085209.8207.4413
2025Q32025-11-030.000-0.012-0.294205.7204.8213
2025Q22025-08-050.050-0.008-3.573213.1201.8616
2025Q12025-05-06-0.030-0.055-0.001195.9200.5417
2024Q42025-02-240.0300.030-0.467210.6211.6217
2024Q32024-11-070.0600.019-0.243213.3210.7615
2024Q22024-08-060.050-0.012-0.405211.5206.4412
2024Q12024-05-07-0.010-0.104-0.289202.2193.5112
2023Q42024-02-270.0400.014-0.362196.6194.812
2023Q32023-11-06-0.030-0.076-0.749191.9182.329
2023Q22023-08-03-0.080-0.081-1.421183.5187.169
2023Q12023-05-03-0.210-0.193-0.673181.2171.499
2022Q42023-02-28-0.120-0.163-0.519177.8169.479

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.6701.7150.061851.1857.38
2020FY-0.080-0.190-2.690638.6639.35
2021FY0.0200.000-0.349690.6691.23
2022FY-0.300-0.343-1.390678.4670.07
2023FY-0.270-0.304-3.180753.2751.44
2024FY0.1400.132-1.405837.6838.87
2025FY0.0600.010-3.950824.5822.22
2026FY--0.698--784.37
2027FY--0.690--746.39
2028FY--0.719--752.44
2029FY--1.375--760.65
2030FY--1.170--837.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-10906192.88190.85196
2026Q4S2026-11-09905193.4191.06196
2026Q4S2026-11-08804193.31191.06196
2026Q4S2026-11-06904194.16191.06200.9
2026Q4S2026-11-05904194.3191.06200.9
2026Q4S2026-11-04801196.11192.98200.9
2026Q4S2026-10-28801196.11192.98200.9
2026Q4S2026-10-21802196.11192.98200.9
2026Q4S2026-10-19803196.11192.98200.9
2026Q4S2026-10-18803196.11192.98200.9
2026Q4S2026-10-14804196.11192.98200.9
2026Q4S2026-10-12807196.11192.98200.9
2026Q4S2026-10-08816196.82192.98202.3
2026Q4S2026-10-06807195.86192.98200.9

Estimate history

EPS, annual1.710.2981.8510.061-0.349-1.39-3.18-1.405-3.951-1.363
Period201620172018201920212022202320242025TTM
EPS, quarterly-0.243-0.467-0.001-3.573-0.294-0.085-0.364-0.456-0.459
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual753.8769.9743.7851.1690.6678.4753.2837.6824.5803.6
Period201620172018201920212022202320242025TTM
Sales, quarterly213.3210.6195.9213.1205.7209.8200.4190.7202.7
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual69.168.470.673.58081.289.991.393.595.7
Period201620172018201920212022202320242025MRQ
Shares, quarterly9191.392.293.193.193.594.495.695.7
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2019FY2018FY
Total Revenue803.60824.50837.60753.20678.40690.60-851.10743.70
Cost of Goods Sold Incl. D&A284.60247.90252.20279.00243.10248.30-260.30214.50
Gross Profit519.00576.60585.40474.20435.30442.30-590.80529.20
Selling, General and Administrative Excl. Other626.10644.40673.00618.80553.60567.20-552.20468.50
Research and Development104.10106.80113.4088.7085.4081.90-85.9070.80
Other Operating Expense0.000.000.000.000.000.00-0.000.00
Operating Income-107.10-67.80-87.60-144.60-118.30-124.90-38.6060.70
Interest Expense16.7010.502.802.903.206.60-12.003.20
Unusual Expense8.10319.4021.30112.8022.3077.30-30.60-61.20
Net Income Before Taxes-129.20-395.10-123.50-262.20-140.60-57.10-0.00120.10
Income Taxes-0.10-29.203.801.10-28.60-29.90--4.40-13.00
Consolidated Net Income-129.10-365.90-127.30-263.30-112.00-27.20-4.40133.10
Net Income From Continuing Operations-129.10-365.90-127.30-263.30-112.00-27.20-4.60133.30
Net Income-129.10-365.90-127.30-263.30-112.00-27.20-4.60133.30
EPS (Recurring)-1.29-1.54-1.24-2.23-1.200.34-0.341.26
EPS (Basic, Before Extraordinaries)-1.36-3.95-1.41-3.18-1.39-0.35-0.061.92
EPS (Diluted)-1.36-3.95-1.41-3.18-1.39-0.35-0.061.85
EBITDA-57.90-13.60-26.00-71.40-53.90-49.30-111.60115.10
Non-Operating Income (Expense)2.702.60-11.80-1.903.20151.70-4.001.40
Other After Tax Adjustments0.000.000.000.000.000.00-0.000.00
Stock Option Compensation Expense23.1827.8139.3432.1530.1026.50-24.4521.41
Price To Earnings Ratio-------93.7919.20
Price To Sales Ratio0.510.691.482.101.723.12-2.483.62
Gross Margin64.5869.9369.8962.9664.1764.05-69.4271.16
Operating Margin-13.33-8.22-10.46-19.20-17.44-18.09-4.548.16
Net Margin-16.07-44.38-15.20-34.96-16.51-3.94-0.5417.92
Shares Outstanding95.7093.5091.3089.9081.2080.00-73.5070.60
Market Capitalization548.67548.671,248.091,573.271,175.802,203.99-2,038.302,612.42

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue202.70190.70200.40209.80205.70213.10195.90210.60
Cost of Goods Sold Incl. D&A72.9071.5070.7069.5069.8070.7061.7059.70
Gross Profit129.80119.20129.70140.30135.90142.40134.20150.90
Selling, General and Administrative Excl. Other169.70158.10155.00143.30159.20154.90163.20168.30
Research and Development26.5025.0027.1025.5028.2025.6027.5029.70
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-39.90-38.90-25.30-3.00-23.30-12.50-29.00-17.40
Interest Expense4.104.104.104.403.801.500.800.70
Unusual Expense0.000.005.402.700.00316.700.0021.60
Net Income Before Taxes-43.60-42.60-34.10-8.90-26.20-330.60-29.40-39.10
Income Taxes0.300.600.00-1.001.20-0.10-29.303.40
Consolidated Net Income-43.90-43.20-34.10-7.90-27.40-330.50-0.10-42.50
Net Income From Continuing Operations-43.90-43.20-34.10-7.90-27.40-330.50-0.10-42.50
Net Income-43.90-43.20-34.10-7.90-27.40-330.50-0.10-42.50
EPS (Recurring)-0.46-0.46-0.32-0.06-0.29-1.18-0.00-0.30
EPS (Basic, Before Extraordinaries)-0.46-0.46-0.36-0.08-0.29-3.57-0.00-0.47
EPS (Diluted)-0.46-0.46-0.36-0.08-0.29-3.57-0.00-0.47
EBITDA-27.10-26.30-12.708.20-10.601.80-14.50-2.70
Non-Operating Income (Expense)0.400.400.701.200.900.100.400.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.277.206.502.219.648.457.508.61
Price To Sales Ratio0.510.670.510.700.820.590.981.49
Gross Margin64.0462.5164.7266.8766.0766.8268.5071.65
Operating Margin-19.68-20.40-12.62-1.43-11.33-5.87-14.80-8.26
Net Margin-21.66-22.65-17.02-3.77-13.32-155.09-0.05-20.18
Shares Outstanding95.7095.6094.4093.5093.1093.1092.2091.30
Market Capitalization548.67539.30420.79573.26672.71489.46809.911,248.09

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017FY
Cash & Short Term Investments149.60111.00142.10116.90339.80-136.90180.60150.70
Short Term Receivables115.30121.20114.30101.6091.30-138.60103.3095.90
Inventories30.6027.5022.0020.1015.30-31.4034.3042.20
Other Current Assets37.1038.3035.2036.0038.40-41.709.4012.90
Total Current Assets332.60298.00313.60274.60484.80-348.60327.60301.70
Net Property, Plant & Equipment163.40172.40180.60187.30125.30-57.3043.2051.10
Total Investments and Advances0.000.907.6062.3059.00-54.9030.7048.50
Intangible Assets205.00548.70636.90666.50643.30-1,101.90773.80807.60
Deferred Tax Assets--100.00118.5092.80-103.0052.2099.00
Other Assets5.607.607.808.008.30-0.000.000.00
Total Assets706.601,027.601,246.501,317.201,413.50-1,665.701,227.501,307.90
Short Term Debt Incl. Current Port. of LT Debt6.9012.8016.2014.1013.00-0.000.000.00
Accounts Payable30.0032.3025.8028.8029.60-33.3026.0022.00
Income Tax Payable5.705.104.604.804.00-3.004.307.10
Other Current Liabilities91.20113.90109.3089.50157.70-81.5071.90188.40
Total Current Liabilities133.80164.10155.90137.20204.30-117.80102.20217.50
Long Term Debt202.90127.50135.90130.9079.30-233.509.3099.10
Provision for Risks Charges0.000.0030.2026.8027.90-28.5030.9044.30
Deferred Tax Liabilities0.2032.70101.60122.00128.60-185.60109.50177.70
Other Liabilities1.702.2039.7014.505.60-11.409.501.30
Total Liabilities338.60326.50463.30431.40445.70-576.80261.40539.90
Non-Equity Reserves0.000.000.000.000.00-0.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00-0.000.000.00
Common Equity368.00701.10783.20885.80967.80-1,088.90966.10768.40
Total Shareholders Equity368.00701.10783.20885.80967.80-1,088.90966.10768.40
Accumulated Minority Interest0.000.000.000.000.00-0.000.00-0.40
Total Equity368.00701.10783.20885.80967.80-1,088.90966.10768.00
Total Liabilities & Stockholders Equity706.601,027.601,246.501,317.201,413.50-1,665.701,227.501,307.90
Book Value Per Share3.947.688.7110.9112.10-14.8113.6811.23
Tangible Book Value Per Share1.741.671.632.704.06--0.182.72-0.57
Full-Time Employees2,7002,7002,7002,6002,400-2,6002,4002,400
Price to Book Ratio2.041.712.301.282.28-1.882.752.27
Return on Assets-42.20-11.20-20.54-8.20-1.84-0.3210.521.82
Return on Equity-68.45-17.15-31.55-12.08-2.88-0.4515.372.70
Return on Invested Capital-64.09-15.36-28.65-11.02-2.60-0.3513.672.36
Quick Ratio2.261.651.871.852.30-2.692.871.19
Current Ratio2.491.822.012.002.37-2.963.211.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2019FY2018FY
Net Income-129.10-365.90-127.30-263.30-112.00-27.20-4.60133.30
Depreciation50.2053.7061.2073.2064.4075.60-73.0054.40
Other Funds (Non Cash)42.70365.70112.1072.5072.90-119.70-24.60-56.80
Funds from Operations-37.1021.1045.70-121.60-5.50-103.40-120.80107.40
Extraordinary Item0.000.000.000.000.000.00-0.000.00
Changes in Working Capital17.20-19.30-54.4010.70-101.50120.40--37.108.50
Cash from Operating Activities-19.901.80-8.70-110.90-107.0017.00-83.70115.90
Capital Expenditures-17.80-27.40-29.70-73.30-45.30-18.00--8.60-8.40
Net Assets From Acquisitions0.000.000.000.00-57.200.00--278.500.00
Sale of Fixed Assets and Businesses0.000.008.800.000.00379.10-0.000.50
Purchase or Sale of Investments0.000.009.00105.2025.00-86.70-0.70-3.20
Purchase of Investments0.000.000.000.00-103.20-147.80--78.50-80.90
Sale Or Maturity of Investments0.000.009.00105.20128.2061.10-79.2077.70
Other Uses0.000.000.000.000.000.00-0.000.00
Other Sources0.000.000.000.000.000.00-0.000.00
Cash from Investing Activities-17.80-27.40-11.9031.90-77.50274.40--286.40-11.10
Cash Dividends Paid0.000.000.000.000.000.00-0.000.00
Change in Capital Stock3.403.305.906.006.3091.80--41.3036.90
Repurchase of Common Pref Stock0.000.000.000.000.000.00--50.000.00
Sale of Common Pref Stock3.403.305.906.006.3091.80-8.7036.90
Proceedsfrom Stock Options0.000.000.000.000.000.00-0.000.00
Issuance or Reduction of Debt, Net-0.6075.900.1038.100.00-226.40-225.00-90.00
Change in Long Term Debt-0.6075.900.1038.100.00-226.40-225.00-90.00
Issuance of Long Term Debt0.00165.00120.0080.000.000.00-340.0053.00
Reduction of Long Term Debt-0.60-89.10-119.90-41.900.00-226.40--115.00-143.00
Net Financing Active Other Cash Flow-12.10-15.00-13.40108.80-13.60-14.80--1.40-42.40
Other Financing Activities Uses-12.10-15.00-13.40-8.80-13.60-14.80--1.40-42.40
Cash from Financing Activities-9.3064.20-7.40152.90-7.30-149.40-182.30-95.50
Exchange Rate Effect0.000.80-1.000.60-0.60-0.60-2.70-0.80
Net Change in Cash-47.0039.40-29.0074.50-192.40141.40--17.708.50
Free Cash Flow-33.90-13.80-27.70-174.10-152.30-1.00-75.10107.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Price to Free Cash Flow-------28.1125.03
Deferred Taxes & Investment Tax Credit--32.40-0.30-4.00-30.80-32.10-18.60-23.50

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments107.10115.20124.40149.60145.4074.40
Short Term Receivables105.50109.50123.80115.30118.00137.00
Inventories28.6030.6027.9030.6031.6028.70
Other Current Assets30.7033.7036.7037.1049.8044.20
Total Current Assets271.90289.00312.80332.60344.80284.30
Net Property, Plant & Equipment153.60158.90162.50163.40162.00164.20
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets178.90186.10192.80205.00214.70221.70
Other Assets4.804.905.605.606.607.10
Total Assets609.20638.90673.70706.60728.10677.30
Short Term Debt Incl. Current Port. of LT Debt7.807.307.106.907.9068.40
Accounts Payable27.6030.4032.6030.0031.8030.90
Income Tax Payable6.306.806.605.705.105.10
Other Current Liabilities95.9086.2083.9091.20103.2095.50
Total Current Liabilities137.60130.70130.20133.80148.00199.90
Long Term Debt201.60203.20204.40202.90204.4086.20
Provision for Risks Charges0.000.000.000.001.201.20
Deferred Tax Liabilities---0.20--
Other Liabilities1.001.101.701.701.701.90
Total Liabilities340.20335.00336.30338.60355.30289.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity269.00303.90337.40368.00372.80388.10
Total Shareholders Equity269.00303.90337.40368.00372.80388.10
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity269.00303.90337.40368.00372.80388.10
Total Liabilities & Stockholders Equity609.20638.90673.70706.60728.10677.30
Book Value Per Share2.813.183.573.944.004.17
Tangible Book Value Per Share0.941.231.531.741.701.79
Full-Time Employees---2,700--
Price to Book Ratio2.041.601.141.541.730.69
Return on Assets-19.31-17.11-47.61-42.20-44.27-44.85
Return on Equity-40.23-32.54-76.73-68.45-72.52-70.03
Return on Invested Capital-9.33-8.52-6.29-1.38-4.75-69.68
Quick Ratio1.771.982.192.262.121.28
Current Ratio1.982.212.402.492.331.42

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-43.90-43.20-34.10-7.90-27.40-330.50
Depreciation12.6012.5012.5012.6012.6014.10
Other Funds (Non Cash)11.209.0014.108.4014.50330.00
Funds from Operations-20.10-21.70-7.5012.20-0.3013.40
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital13.6013.40-8.20-1.6021.40-27.00
Cash from Operating Activities-6.50-8.30-15.7010.6021.10-13.60
Capital Expenditures-2.10-3.20-6.50-6.00-6.20-6.90
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.10-3.20-6.50-6.00-6.20-6.90
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.002.800.000.600.002.70
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.002.800.000.600.002.70
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.10-0.20-0.10-0.2056.600.00
Change in Long Term Debt-0.10-0.20-0.10-0.2056.600.00
Issuance of Long Term Debt0.000.000.000.00125.000.00
Reduction of Long Term Debt-0.10-0.20-0.10-0.20-68.400.00
Net Financing Active Other Cash Flow-0.20-0.40-2.90-8.60-0.40-0.10
Other Financing Activities Uses-0.20-0.40-2.90-8.60-0.40-0.10
Cash from Financing Activities-0.302.20-3.00-8.2056.202.60
Exchange Rate Effect-0.100.10-0.100.100.000.60
Net Change in Cash-9.00-9.20-25.30-3.5071.10-17.30
Free Cash Flow-8.30-10.40-21.105.9018.30-16.40

Revenue breakdown

Hereditary Cancer2024: 364.50M 2025: 372.40M
Mental Health2024: 170.20M 2025: 144.10M
Prenatal2024: 177.10M 2025: 186.30M
Tumor Profiling2024: 125.80M 2025: 121.70M
Non-US2024: 68.10M 2025: 56.50M
United States2024: 769.50M 2025: 768.00M
Hereditary Cancer2024: 364.50M 2025: 372.40M
Mental Health2024: 170.20M 2025: 144.10M
Prenatal2024: 177.10M 2025: 186.30M
Tumor Profiling2024: 125.80M 2025: 121.70M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.52%8.4M88.6M2.62M
2026-10-1510.46%9.3M88.6M2.06M
2026-09-309.65%8.5M88.6M1.96M
2026-09-1510.55%9.3M88.6M1.95M
2026-08-318.82%7.8M89.0M1.84M
2026-08-148.65%7.7M88.9M1.91M
2026-07-319.55%8.5M89.0M1.85M
2026-07-159.12%8.0M87.9M1.63M
2026-06-309.75%8.6M87.9M1.61M
2026-06-159.85%8.7M87.8M1.82M
2026-05-299.67%8.6M88.4M1.91M
2026-05-159.42%8.3M88.4M1.90M
2026-04-308.95%7.9M88.1M1.71M
2026-04-159.46%8.2M87.1M1.71M
2026-03-319.85%8.8M89.0M1.69M
2026-03-1313.15%11.7M89.0M1.29M
2026-02-2713.07%11.6M89.0M1.09M
2026-02-1312.11%10.8M89.0M999.65K
2026-01-3012.02%10.7M88.7M1.06M
2026-01-1511.63%10.3M88.8M1.05M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.003.505.902.800.0001.000.000.985-0.0130.000
call2.001.655.100.0016.7450.000.000.973-0.0130.001
call3.001.404.003.0510.1165.000.000.958-0.0130.001
call4.001.352.101.803.4372081.000.932-0.0120.001
call5.000.501.251.382.5412590.000.786-0.0190.003
call6.000.000.400.231.4496020.000.470-0.0310.004
call7.000.002.000.252.2926330.000.350-0.0430.003
call8.000.002.150.302.8993090.000.303-0.0510.003
call9.000.001.150.403.3842000.000.276-0.0570.003
call10.000.002.150.053.7891560.000.257-0.0620.003
call11.000.001.000.004.1360.000.000.244-0.0650.003
put1.000.000.050.066.51610.000.00-0.015-0.0120.000
put2.000.000.050.043.99552.000.00-0.027-0.0120.001
put3.000.000.500.052.7611070.00-0.042-0.0120.001
put4.000.000.050.034.4162740.00-0.186-0.0600.002
put5.000.000.150.101.2543771.00-0.214-0.0180.003
put6.000.200.800.651.80551.000.00-0.530-0.0300.004
put7.000.202.451.774.51611.000.00-0.650-0.0420.003
put8.000.304.500.008.2040.000.00-0.697-0.0500.003
put9.002.155.400.008.4180.000.00-0.724-0.0560.003
put10.003.106.405.698.8541.000.00-0.743-0.0610.003
put11.004.106.700.007.2380.000.00-0.756-0.0640.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-098-KCurrent report2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-02SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-208-KCurrent report2026-10-19SEC
2026-10-098-KCurrent report2026-10-06SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-173Initial statement of beneficial ownership of securities2026-09-16SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-04SCHEDULE 13GSEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-16SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-07SCHEDULE 13GSEC
2026-07-3110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-238-KCurrent report2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060066.84K1
2026-0527.64K100
2026-040000
2026-03199.84K100
2026-02494.72K300
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.11.53%
MILLENNIUM MANAGEMENT LLC7.01%
Vestal Point Capital, LP6.07%
STATE STREET CORP5.28%
D. E. Shaw & Co., Inc.4.85%
VANGUARD CAPITAL MANAGEMENT LLC4.32%
ACADIAN ASSET MANAGEMENT LLC3.62%
VANGUARD PORTFOLIO MANAGEMENT LLC3.26%
AQR CAPITAL MANAGEMENT LLC2.93%
MORGAN STANLEY2.63%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.19%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.05%
iShares Russell 2000 ETF2.56%
BlackRock Advantage Small Cap Core Fund1.87%
abrdn Healthcare Opportunities Fund1.39%
Nuveen Quant Small Cap Equity Fund1.30%
Federated Hermes MDT Small Cap Core Fund1.18%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
VANGUARD STRATEGIC EQUITY FUND1.08%
Fidelity Small Cap Index Fund1.07%

OakChart. MYGN. Cached 15 minutes.